FFO
LENZ

Fortitude Family Office’s LENZ Therapeutics LENZ Stock Holding History

Fortitude Family Office’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$375 Buy
+41
New +$576 ﹤0.01% 1805
2025
Q2 		– Sell
-9
Closed -$231 – 2156
2025
Q1 		$231 Hold
9
– – ﹤0.01% 1112
2024
Q4 		$260 Buy
+9
New +$274 ﹤0.01% 1249

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Fortitude Family Office's LENZ Position: Q1 2026 in Review

Fortitude Family Office opened a new position in LENZ Therapeutics (LENZ) in Q1 2026: 41 shares worth $375. The stake represents ﹤0.01% of the portfolio and ranks #1805 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in LENZ as recently as Q1 2025.

Fortitude Family Office first reported a position in LENZ in Q4 2024 and has held it in 3 quarters since. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Fortitude Family Office held 41 shares of LENZ Therapeutics worth $375 as of Q1 2026.
  • LENZ Therapeutics was a new Fortitude Family Office position in Q1 2026.
  • LENZ Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q1 2026, its #1805 holding.
  • Fortitude Family Office first reported a position in LENZ Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.